AU2018378078B2 - IL-2 muteins and uses thereof - Google Patents

IL-2 muteins and uses thereof Download PDF

Info

Publication number: AU2018378078B2
Authority: AU; Australia
Prior art keywords: peptide; seq; juvenile; disease; sequence
Prior art date: 2017-12-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

AU2018378078A

Other languages

English (en)

Other versions

AU2018378078A1 (en

Inventor

Nathan HIGGINSON-SCOTT

Kevin Lewis Otipoby

Erik Robert Sampson

Joanne L. Viney

Jyothsna Visweswaraiah

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pandion Operations Inc

Original Assignee

Pandion Operations Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-12-06

Filing date

2018-11-28

Publication date

2024-07-25

2018-08-23 Priority claimed from US16/109,875 external-priority patent/US10174091B1/en

2018-11-28 Application filed by Pandion Operations Inc filed Critical Pandion Operations Inc

2020-06-18 Publication of AU2018378078A1 publication Critical patent/AU2018378078A1/en

2020-10-29 Assigned to Pandion Operations, Inc. reassignment Pandion Operations, Inc. Amend patent request/document other than specification (104) Assignors: Pandion Therapeutics, Inc.

2024-07-25 Application granted granted Critical

2024-07-25 Publication of AU2018378078B2 publication Critical patent/AU2018378078B2/en

2024-08-29 Priority to AU2024216451A priority Critical patent/AU2024216451A1/en

Status Active legal-status Critical Current

2038-11-28 Anticipated expiration legal-status Critical

Links

108010002350 Interleukin-2 Proteins 0.000 title abstract description 173
238000000034 method Methods 0.000 claims abstract description 40
239000003814 drug Substances 0.000 claims abstract description 11
108090000765 processed proteins & peptides Proteins 0.000 claims description 242
210000004027 cell Anatomy 0.000 claims description 59
210000003289 regulatory T cell Anatomy 0.000 claims description 37
230000000366 juvenile effect Effects 0.000 claims description 30
150000007523 nucleic acids Chemical class 0.000 claims description 29
102000039446 nucleic acids Human genes 0.000 claims description 28
108020004707 nucleic acids Proteins 0.000 claims description 28
239000008194 pharmaceutical composition Substances 0.000 claims description 28
206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 25
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
206010039073 rheumatoid arthritis Diseases 0.000 claims description 24
201000010099 disease Diseases 0.000 claims description 23
239000013598 vector Substances 0.000 claims description 23
208000003456 Juvenile Arthritis Diseases 0.000 claims description 20
208000002574 reactive arthritis Diseases 0.000 claims description 20
208000011580 syndromic disease Diseases 0.000 claims description 20
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 19
238000011282 treatment Methods 0.000 claims description 18
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 15
201000004681 Psoriasis Diseases 0.000 claims description 15
206010047115 Vasculitis Diseases 0.000 claims description 15
201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 15
108010076504 Protein Sorting Signals Proteins 0.000 claims description 14
206010061218 Inflammation Diseases 0.000 claims description 12
208000023275 Autoimmune disease Diseases 0.000 claims description 11
208000027866 inflammatory disease Diseases 0.000 claims description 11
230000004054 inflammatory process Effects 0.000 claims description 11
206010003253 Arthritis enteropathic Diseases 0.000 claims description 10
206010003267 Arthritis reactive Diseases 0.000 claims description 10
208000036487 Arthropathies Diseases 0.000 claims description 10
208000012659 Joint disease Diseases 0.000 claims description 10
208000033464 Reiter syndrome Diseases 0.000 claims description 10
108010029477 STAT5 Transcription Factor Proteins 0.000 claims description 10
206010039710 Scleroderma Diseases 0.000 claims description 10
208000034189 Sclerosis Diseases 0.000 claims description 10
208000019069 chronic childhood arthritis Diseases 0.000 claims description 10
201000001981 dermatomyositis Diseases 0.000 claims description 10
206010014910 enthesopathy Diseases 0.000 claims description 10
201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims description 10
231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims description 10
210000003734 kidney Anatomy 0.000 claims description 10
201000006417 multiple sclerosis Diseases 0.000 claims description 10
201000009890 sinusitis Diseases 0.000 claims description 10
230000009885 systemic effect Effects 0.000 claims description 10
208000009329 Graft vs Host Disease Diseases 0.000 claims description 9
208000017760 chronic graft versus host disease Diseases 0.000 claims description 9
208000024908 graft versus host disease Diseases 0.000 claims description 9
150000003431 steroids Chemical class 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 8
230000004936 stimulating effect Effects 0.000 claims description 8
201000004384 Alopecia Diseases 0.000 claims description 6
231100000360 alopecia Toxicity 0.000 claims description 6
239000013612 plasmid Substances 0.000 claims description 6
XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims description 5
208000026872 Addison Disease Diseases 0.000 claims description 5
206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 5
201000001320 Atherosclerosis Diseases 0.000 claims description 5
208000012657 Atopic disease Diseases 0.000 claims description 5
206010003827 Autoimmune hepatitis Diseases 0.000 claims description 5
208000023328 Basedow disease Diseases 0.000 claims description 5
206010008609 Cholangitis sclerosing Diseases 0.000 claims description 5
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
208000015943 Coeliac disease Diseases 0.000 claims description 5
206010009900 Colitis ulcerative Diseases 0.000 claims description 5
208000011231 Crohn disease Diseases 0.000 claims description 5
201000004624 Dermatitis Diseases 0.000 claims description 5
206010012438 Dermatitis atopic Diseases 0.000 claims description 5
206010065563 Eosinophilic bronchitis Diseases 0.000 claims description 5
206010015278 Erythrodermic psoriasis Diseases 0.000 claims description 5
206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 claims description 5
206010018372 Glomerulonephritis membranous Diseases 0.000 claims description 5
206010018374 Glomerulonephritis minimal lesion Diseases 0.000 claims description 5
206010051920 Glomerulonephropathy Diseases 0.000 claims description 5
206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 5
208000015023 Graves' disease Diseases 0.000 claims description 5
208000005176 Hepatitis C Diseases 0.000 claims description 5
208000010159 IgA glomerulonephritis Diseases 0.000 claims description 5
206010021263 IgA nephropathy Diseases 0.000 claims description 5
208000012528 Juvenile dermatomyositis Diseases 0.000 claims description 5
208000004883 Lipoid Nephrosis Diseases 0.000 claims description 5
208000005777 Lupus Nephritis Diseases 0.000 claims description 5
208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims description 5
208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 claims description 5
201000001263 Psoriatic Arthritis Diseases 0.000 claims description 5
208000036824 Psoriatic arthropathy Diseases 0.000 claims description 5
206010037575 Pustular psoriasis Diseases 0.000 claims description 5
208000012322 Raynaud phenomenon Diseases 0.000 claims description 5
208000021386 Sjogren Syndrome Diseases 0.000 claims description 5
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 5
201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
206010047642 Vitiligo Diseases 0.000 claims description 5
206010003230 arteritis Diseases 0.000 claims description 5
206010003246 arthritis Diseases 0.000 claims description 5
208000006673 asthma Diseases 0.000 claims description 5
201000008937 atopic dermatitis Diseases 0.000 claims description 5
210000000845 cartilage Anatomy 0.000 claims description 5
201000010415 childhood type dermatomyositis Diseases 0.000 claims description 5
208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 5
230000006378 damage Effects 0.000 claims description 5
230000002327 eosinophilic effect Effects 0.000 claims description 5
206010018797 guttate psoriasis Diseases 0.000 claims description 5
210000002216 heart Anatomy 0.000 claims description 5
201000004990 juvenile ankylosing spondylitis Diseases 0.000 claims description 5
210000004072 lung Anatomy 0.000 claims description 5
206010025135 lupus erythematosus Diseases 0.000 claims description 5
201000008350 membranous glomerulonephritis Diseases 0.000 claims description 5
231100000855 membranous nephropathy Toxicity 0.000 claims description 5
206010028417 myasthenia gravis Diseases 0.000 claims description 5
230000026731 phosphorylation Effects 0.000 claims description 5
238000006366 phosphorylation reaction Methods 0.000 claims description 5
208000012102 polyarticular juvenile rheumatoid arthritis Diseases 0.000 claims description 5
230000035935 pregnancy Effects 0.000 claims description 5
201000000306 sarcoidosis Diseases 0.000 claims description 5
208000010157 sclerosing cholangitis Diseases 0.000 claims description 5
210000003491 skin Anatomy 0.000 claims description 5
230000002269 spontaneous effect Effects 0.000 claims description 5
206010043778 thyroiditis Diseases 0.000 claims description 5
238000002054 transplantation Methods 0.000 claims description 5
230000001737 promoting effect Effects 0.000 claims description 4
206010012468 Dermatitis herpetiformis Diseases 0.000 claims description 3
230000003213 activating effect Effects 0.000 claims description 3
208000004631 alopecia areata Diseases 0.000 claims description 3
125000003275 alpha amino acid group Chemical group 0.000 claims 2
102000001712 STAT5 Transcription Factor Human genes 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 abstract description 43
150000001875 compounds Chemical class 0.000 abstract description 34
239000000203 mixture Substances 0.000 abstract description 32
239000003937 drug carrier Substances 0.000 abstract description 5
230000004913 activation Effects 0.000 abstract description 4
230000004083 survival effect Effects 0.000 abstract description 4
230000004663 cell proliferation Effects 0.000 abstract description 3
102000000588 Interleukin-2 Human genes 0.000 description 170
230000035772 mutation Effects 0.000 description 152
108090000623 proteins and genes Proteins 0.000 description 58
102000004169 proteins and genes Human genes 0.000 description 56
235000018102 proteins Nutrition 0.000 description 55
238000006467 substitution reaction Methods 0.000 description 41
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 40
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 30
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 30
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 30
102220519030 Guanylyl cyclase-activating protein 1_L80I_mutation Human genes 0.000 description 27
150000001413 amino acids Chemical group 0.000 description 25
102220585301 PHD and RING finger domain-containing protein 1_L56I_mutation Human genes 0.000 description 22
102000004196 processed proteins & peptides Human genes 0.000 description 17
235000001014 amino acid Nutrition 0.000 description 15
102220274636 rs144712084 Human genes 0.000 description 15
101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 14
229940024606 amino acid Drugs 0.000 description 14
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 14
102100027581 Forkhead box protein P3 Human genes 0.000 description 13
210000004369 blood Anatomy 0.000 description 13
239000008280 blood Substances 0.000 description 13
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 12
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 12
239000011534 wash buffer Substances 0.000 description 12
102220602660 Argininosuccinate synthase_V69A_mutation Human genes 0.000 description 11
239000000872 buffer Substances 0.000 description 11
102200053439 rs72466487 Human genes 0.000 description 11
241000699670 Mus sp. Species 0.000 description 10
-1 Ras-MAP -kinase Proteins 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
235000014966 Eragrostis abyssinica Nutrition 0.000 description 9
102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 9
229920001184 polypeptide Polymers 0.000 description 9
210000001744 T-lymphocyte Anatomy 0.000 description 8
238000003556 assay Methods 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
101710099484 Aminopeptidase T Proteins 0.000 description 7
241000282693 Cercopithecidae Species 0.000 description 7
101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 7
230000004927 fusion Effects 0.000 description 7
238000001802 infusion Methods 0.000 description 7
235000014705 isoleucine Nutrition 0.000 description 7
230000003389 potentiating effect Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 6
108091028043 Nucleic acid sequence Proteins 0.000 description 6
229920001213 Polysorbate 20 Polymers 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000012131 assay buffer Substances 0.000 description 6
230000027455 binding Effects 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
229960000310 isoleucine Drugs 0.000 description 6
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 6
210000000822 natural killer cell Anatomy 0.000 description 6
230000008823 permeabilization Effects 0.000 description 6
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
239000011347 resin Substances 0.000 description 6
229920005989 resin Polymers 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
238000001542 size-exclusion chromatography Methods 0.000 description 6
108020004414 DNA Proteins 0.000 description 5
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
239000004698 Polyethylene Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
210000003743 erythrocyte Anatomy 0.000 description 5
238000001914 filtration Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
239000000463 material Substances 0.000 description 5
230000037361 pathway Effects 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
238000013207 serial dilution Methods 0.000 description 5
230000011664 signaling Effects 0.000 description 5
229940124597 therapeutic agent Drugs 0.000 description 5
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 4
108700028369 Alleles Proteins 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
239000004471 Glycine Substances 0.000 description 4
101000716700 Mesobuthus martensii Toxin BmKT Proteins 0.000 description 4
102220472091 Protein ENL_D20T_mutation Human genes 0.000 description 4
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
239000012091 fetal bovine serum Substances 0.000 description 4
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
102220273516 rs768267292 Human genes 0.000 description 4
102220097722 rs876660020 Human genes 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
102220638992 Beta-enolase_H16D_mutation Human genes 0.000 description 3
102220638984 Beta-enolase_H16K_mutation Human genes 0.000 description 3
102000019034 Chemokines Human genes 0.000 description 3
108010012236 Chemokines Proteins 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
102220626060 HMG box transcription factor BBX_D84A_mutation Human genes 0.000 description 3
101100220044 Homo sapiens CD34 gene Proteins 0.000 description 3
101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 3
102220595270 Minor histocompatibility protein HB-1_H16R_mutation Human genes 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
102220546836 Nuclear pore complex protein Nup85_L19D_mutation Human genes 0.000 description 3
102220585295 PHD and RING finger domain-containing protein 1_D84G_mutation Human genes 0.000 description 3
102100038823 RNA-binding protein 45 Human genes 0.000 description 3
239000012979 RPMI medium Substances 0.000 description 3
102220622777 Sphingomyelin phosphodiesterase_N88G_mutation Human genes 0.000 description 3
102220503468 Superoxide dismutase [Cu-Zn]_D84S_mutation Human genes 0.000 description 3
102220572215 Toll-interacting protein_K35R_mutation Human genes 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
230000002776 aggregation Effects 0.000 description 3
238000004220 aggregation Methods 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
210000004102 animal cell Anatomy 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
102220412918 c.59A>G Human genes 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000012228 culture supernatant Substances 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
210000003162 effector t lymphocyte Anatomy 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000000684 flow cytometry Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
210000003958 hematopoietic stem cell Anatomy 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
102220110995 rs115116507 Human genes 0.000 description 3
102200006183 rs11552822 Human genes 0.000 description 3
102200139516 rs35960830 Human genes 0.000 description 3
102220095978 rs876658926 Human genes 0.000 description 3
102220094066 rs876659747 Human genes 0.000 description 3
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
210000004988 splenocyte Anatomy 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000000829 suppository Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
102220481485 11-beta-hydroxysteroid dehydrogenase type 2_E115Q_mutation Human genes 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
102220638990 Beta-enolase_H16A_mutation Human genes 0.000 description 2
102220638986 Beta-enolase_H16S_mutation Human genes 0.000 description 2
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
241000283707 Capra Species 0.000 description 2
102220598064 Cell division cycle and apoptosis regulator protein 1_N88A_mutation Human genes 0.000 description 2
241000233866 Fungi Species 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
102220470904 Interferon-induced protein with tetratricopeptide repeats 5_K48E_mutation Human genes 0.000 description 2
102220511586 Kappa-casein_D84R_mutation Human genes 0.000 description 2
102220645750 Keratin-associated protein 6-3_Y51S_mutation Human genes 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
102220479935 Leucine-rich repeat-containing protein 26_R81A_mutation Human genes 0.000 description 2
102000043131 MHC class II family Human genes 0.000 description 2
108091054438 MHC class II family Proteins 0.000 description 2
102220595293 Minor histocompatibility protein HB-1_H16Y_mutation Human genes 0.000 description 2
102220546830 Nuclear pore complex protein Nup85_L19A_mutation Human genes 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
102220517143 Phosphate-regulating neutral endopeptidase PHEX_D84E_mutation Human genes 0.000 description 2
102220517148 Phosphate-regulating neutral endopeptidase PHEX_D84Q_mutation Human genes 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
102220644368 Prelamin-A/C_L19R_mutation Human genes 0.000 description 2
102220550572 Proteasome maturation protein_L19E_mutation Human genes 0.000 description 2
102220486612 Protein YAE1 homolog_K68E_mutation Human genes 0.000 description 2
102220640550 Putative oxidoreductase GLYR1_L19S_mutation Human genes 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
102220494399 Signal transducer and activator of transcription 5A_Y31H_mutation Human genes 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
239000012505 Superdex™ Substances 0.000 description 2
102220572243 Toll-interacting protein_N29S_mutation Human genes 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
102220346405 c.164A>G Human genes 0.000 description 2
102220351326 c.35T>A Human genes 0.000 description 2
102220357126 c.58G>T Human genes 0.000 description 2
238000012754 cardiac puncture Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
238000004590 computer program Methods 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000002612 dispersion medium Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000012636 effector Substances 0.000 description 2
239000007920 enema Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
125000003827 glycol group Chemical group 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
238000011577 humanized mouse model Methods 0.000 description 2
230000008004 immune attack Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
239000003547 immunosorbent Substances 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000012405 in silico analysis Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
239000002502 liposome Substances 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000000873 masking effect Effects 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000013014 purified material Substances 0.000 description 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
102200000390 rs121917859 Human genes 0.000 description 2
102220091161 rs142951316 Human genes 0.000 description 2
102220249043 rs145159429 Human genes 0.000 description 2
102220044804 rs149101834 Human genes 0.000 description 2
102200066678 rs1554618767 Human genes 0.000 description 2
102220065900 rs200290535 Human genes 0.000 description 2
102220127451 rs267597943 Human genes 0.000 description 2
102220112880 rs370986101 Human genes 0.000 description 2
102200134447 rs41295338 Human genes 0.000 description 2
102200027868 rs62516151 Human genes 0.000 description 2
102220053978 rs727503162 Human genes 0.000 description 2
102220146061 rs758345818 Human genes 0.000 description 2
102220120718 rs886042647 Human genes 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
229960002930 sirolimus Drugs 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
239000004474 valine Substances 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
102220579314 ARF GTPase-activating protein GIT1_L12S_mutation Human genes 0.000 description 1
206010001766 Alopecia totalis Diseases 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
102220638985 Beta-enolase_H16E_mutation Human genes 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000792859 Enema Species 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
102220485773 Glycophorin-A_L94I_mutation Human genes 0.000 description 1
102220541510 Golgi to ER traffic protein 4 homolog_D84K_mutation Human genes 0.000 description 1
102220493580 HLA class II histocompatibility antigen, DR beta 3 chain_L96I_mutation Human genes 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
102220574082 Histone H3.Y_L63I_mutation Human genes 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
101000863884 Homo sapiens Sialic acid-binding Ig-like lectin 8 Proteins 0.000 description 1
108700001097 Insect Genes Proteins 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
108700005443 Microbial Genes Proteins 0.000 description 1
241000238367 Mya arenaria Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
102220637623 Phytanoyl-CoA hydroxylase-interacting protein-like_L76I_mutation Human genes 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
241000288906 Primates Species 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
102220640548 Putative oxidoreductase GLYR1_N30S_mutation Human genes 0.000 description 1
241000700159 Rattus Species 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
102220573471 Tyrosine-protein kinase Fer_L59I_mutation Human genes 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000013528 artificial neural network Methods 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000006189 buccal tablet Substances 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
210000004970 cd4 cell Anatomy 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229940112822 chewing gum Drugs 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000002052 colonoscopy Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000013329 compounding Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000001839 endoscopy Methods 0.000 description 1
229940095399 enema Drugs 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000012997 ficoll-paque Substances 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000004554 glutamine Nutrition 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
102000053917 human FOXP3 Human genes 0.000 description 1
102000049018 human NCAM1 Human genes 0.000 description 1
102000051056 human SIGLEC8 Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000013394 immunophenotyping Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
150000002520 isoleucines Chemical group 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
239000013642 negative control Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
230000005180 public health Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000004223 radioprotective effect Effects 0.000 description 1
229940099538 rapamune Drugs 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
102200006514 rs121913236 Human genes 0.000 description 1
102220279255 rs1554817540 Human genes 0.000 description 1
102200092592 rs36078803 Human genes 0.000 description 1
102200100726 rs61752874 Human genes 0.000 description 1
102220092592 rs757653096 Human genes 0.000 description 1
102220064955 rs786205425 Human genes 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000008299 semisolid dosage form Substances 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
102000027257 transmembrane receptors Human genes 0.000 description 1
108091008578 transmembrane receptors Proteins 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
238000009777 vacuum freeze-drying Methods 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Transplantation (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AU2018378078A 2017-12-06 2018-11-28 IL-2 muteins and uses thereof Active AU2018378078B2 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
AU2024216451A AU2024216451A1 (en)	2017-12-06	2024-08-29	IL-2 muteins and uses thereof

Applications Claiming Priority (11)

Application Number	Priority Date	Filing Date	Title
US201762595357P	2017-12-06	2017-12-06
US62/595,357		2017-12-06
US201862675972P	2018-05-24	2018-05-24
US62/675,972		2018-05-24
US201862721644P	2018-08-23	2018-08-23
US16/109,875		2018-08-23
US16/109,897		2018-08-23
US16/109,875 US10174091B1 (en)	2017-12-06	2018-08-23	IL-2 muteins
US16/109,897 US10174092B1 (en)	2017-12-06	2018-08-23	IL-2 muteins
US62/721,644		2018-08-23
PCT/US2018/062808 WO2019112854A1 (fr)	2017-12-06	2018-11-28	Mutéines d'il-2 et leurs utilisations

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2024216451A Division AU2024216451A1 (en)	2017-12-06	2024-08-29	IL-2 muteins and uses thereof

Publications (2)

Publication Number	Publication Date
AU2018378078A1 AU2018378078A1 (en)	2020-06-18
AU2018378078B2 true AU2018378078B2 (en)	2024-07-25

Family

ID=66751187

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AU2018378078A Active AU2018378078B2 (en)	2017-12-06	2018-11-28	IL-2 muteins and uses thereof
AU2024216451A Pending AU2024216451A1 (en)	2017-12-06	2024-08-29	IL-2 muteins and uses thereof

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AU2024216451A Pending AU2024216451A1 (en)	2017-12-06	2024-08-29	IL-2 muteins and uses thereof

Country Status (12)

Country	Link
EP (1)	EP3720470A4 (fr)
JP (1)	JP7250790B2 (fr)
KR (3)	KR20240115352A (fr)
CN (2)	CN118515780A (fr)
AU (2)	AU2018378078B2 (fr)
BR (1)	BR112020011343A2 (fr)
CA (1)	CA3083941A1 (fr)
IL (1)	IL274844A (fr)
MX (1)	MX2020005208A (fr)
SG (1)	SG11202003965VA (fr)
WO (1)	WO2019112854A1 (fr)
ZA (1)	ZA202003386B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN110520436A (zh)	2017-03-15	2019-11-29	潘迪恩治疗公司	靶向免疫耐受性
CN111010866A (zh)	2017-05-24	2020-04-14	潘迪恩治疗公司	靶向免疫耐受性
EP3720871A4 (fr) *	2017-12-06	2021-09-15	Pandion Operations, Inc.	Immunotolérance ciblée
US10946068B2 (en)	2017-12-06	2021-03-16	Pandion Operations, Inc.	IL-2 muteins and uses thereof
US10174091B1 (en)	2017-12-06	2019-01-08	Pandion Therapeutics, Inc.	IL-2 muteins
TW202110885A (zh)	2019-05-20	2021-03-16	美商潘迪恩治療公司	靶向ＭＡｄＣＡＭ之免疫耐受性
PH12022550165A1 (en)	2019-07-26	2023-05-08	Visterra Inc	Interleukin-2 agents and uses thereof
CN114728179A (zh) *	2019-08-19	2022-07-08	潘迪恩运营公司	利用pd-1激动剂的靶向免疫耐受
CN110642934B (zh) *	2019-09-10	2022-08-23	中国医学科学院北京协和医院	靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
CA3157859A1 (fr) *	2019-10-15	2021-04-22	Modernatx, Inc.	Arnm codant des polypeptides de modulation immunitaire et leurs utilisations
MX2022007754A (es)	2019-12-20	2022-07-19	Regeneron Pharma	Nuevos agonistas de il2 y metodos de uso de estos.
EP4107187A4 (fr)	2020-02-21	2024-07-03	Pandion Operations, Inc.	Immunotolérance ciblée sur un tissu avec un effecteur cd39
CN112358540A (zh) *	2020-11-03	2021-02-12	安徽环球基因科技有限公司	一种重组il2在毕赤酵母中的生产方法
EP4255466A1 (fr)	2020-12-04	2023-10-11	Visterra, Inc.	Procédés d'utilisation d'agents d'interleukine-2
WO2023165553A1 (fr) *	2022-03-03	2023-09-07	海南先声药业有限公司	Composition pharmaceutique de protéine de fusion de bloc fc d'anticorps-mutant il2 et son utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20140286898A1 (en) *	2013-03-14	2014-09-25	Amgen Inc.	Interleukin-2 muteins for the expansion of t-regulatory cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1007907B (zh) *	1985-04-30	1990-05-09	弗·哈夫曼-拉罗彻有限公司	重组人类白细胞介素-2的提纯
US7569215B2 (en) *	2003-07-18	2009-08-04	Massachusetts Institute Of Technology	Mutant interleukin-2 (IL-2) polypeptides
WO2012088446A1 (fr) *	2010-12-22	2012-06-28	Board Of Trustees Of The Leland Stanford Junior University	Super-agonistes et antagonistes de l'interleukine-2
EP2714198A1 (fr) *	2011-05-31	2014-04-09	Novo Nordisk A/S	Epitopes de il-21 et ligands de il-21
HUE046065T2 (hu) *	2014-07-21	2020-01-28	Delinia Inc	Szabályozó T-sejteket szelektíven aktiváló molekulák autoimmun betegségek kezelésére
CN109071623B (zh) *	2016-05-04	2022-05-27	美国安进公司	用于扩增t调节性细胞的白细胞介素-2突变蛋白
CN110382525B (zh) *	2017-04-03	2023-10-20	豪夫迈·罗氏有限公司	免疫缀合物
CN111010866A (zh) *	2017-05-24	2020-04-14	潘迪恩治疗公司	靶向免疫耐受性
EP3720871A4 (fr) *	2017-12-06	2021-09-15	Pandion Operations, Inc.	Immunotolérance ciblée
EP3876986A4 (fr) *	2018-09-18	2022-06-01	Pandion Operations, Inc.	Immunotolérance ciblée

2018
- 2018-11-28 KR KR1020247023942A patent/KR20240115352A/ko active Pending
- 2018-11-28 WO PCT/US2018/062808 patent/WO2019112854A1/fr unknown
- 2018-11-28 AU AU2018378078A patent/AU2018378078B2/en active Active
- 2018-11-28 JP JP2020530653A patent/JP7250790B2/ja active Active
- 2018-11-28 EP EP18887098.4A patent/EP3720470A4/fr active Pending
- 2018-11-28 CA CA3083941A patent/CA3083941A1/fr active Pending
- 2018-11-28 CN CN202410591221.4A patent/CN118515780A/zh active Pending
- 2018-11-28 SG SG11202003965VA patent/SG11202003965VA/en unknown
- 2018-11-28 MX MX2020005208A patent/MX2020005208A/es unknown
- 2018-11-28 KR KR1020247008135A patent/KR102684426B1/ko active Active
- 2018-11-28 BR BR112020011343-3A patent/BR112020011343A2/pt unknown
- 2018-11-28 KR KR1020207017255A patent/KR102687035B1/ko active Active
- 2018-11-28 CN CN201880077653.6A patent/CN111432831B/zh active Active
2020
- 2020-05-21 IL IL274844A patent/IL274844A/en unknown
- 2020-06-05 ZA ZA2020/03386A patent/ZA202003386B/en unknown
2024
- 2024-08-29 AU AU2024216451A patent/AU2024216451A1/en active Pending

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20140286898A1 (en) *	2013-03-14	2014-09-25	Amgen Inc.	Interleukin-2 muteins for the expansion of t-regulatory cells

Also Published As

Publication number	Publication date
AU2024216451A1 (en)	2024-09-26
KR20240039201A (ko)	2024-03-26
ZA202003386B (en)	2025-04-30
SG11202003965VA (en)	2020-06-29
CN118515780A (zh)	2024-08-20
EP3720470A1 (fr)	2020-10-14
KR102684426B1 (ko)	2024-07-11
JP2021507690A (ja)	2021-02-25
IL274844A (en)	2020-07-30
EP3720470A4 (fr)	2021-09-15
MX2020005208A (es)	2020-08-20
BR112020011343A2 (pt)	2020-11-17
CA3083941A1 (fr)	2019-06-13
WO2019112854A1 (fr)	2019-06-13
KR20240115352A (ko)	2024-07-25
AU2018378078A1 (en)	2020-06-18
KR102687035B1 (ko)	2024-07-22
CN111432831B (zh)	2024-08-16
CN111432831A (zh)	2020-07-17
JP7250790B2 (ja)	2023-04-03
KR20200097275A (ko)	2020-08-18

Publication	Publication Date	Title
US11945852B2 (en)	2024-04-02	IL-2 muteins and uses thereof
AU2018378078B2 (en)	2024-07-25	IL-2 muteins and uses thereof
US11779632B2 (en)	2023-10-10	IL-2 muteins and uses thereof
EP3013859B1 (fr)	2018-05-30	Molécules bispécifiques capables de se lier spécifiquement à la fois à ctla-4 et cd40
WO2020119728A1 (fr)	2020-06-18	Anticorps monoclonal anti-interleukine 5(il-5) humaine et son utilisation
AU2013223801B2 (en)	2016-02-25	Tumour necrosis factor receptor fusion proteins and methods of using the same
US20230265145A1 (en)	2023-08-24	Il-10 muteins and fusion proteins thereof
EA042572B1 (ru)	2023-02-27	Мутеины il-2 и способы их применения
HK40034288A (en)	2021-04-23	Il-2 muteins and uses thereof

Legal Events

Date	Code	Title	Description
2020-10-29	HB	Alteration of name in register	Owner name: PANDION OPERATIONS, INC. Free format text: FORMER NAME(S): PANDION THERAPEUTICS, INC.
2024-11-21	FGA	Letters patent sealed or granted (standard patent)

Date

Code

Title

Description

2020-10-29

Alteration of name in register

Owner name: PANDION OPERATIONS, INC.

Free format text: FORMER NAME(S): PANDION THERAPEUTICS, INC.

2024-11-21

FGA

Letters patent sealed or granted (standard patent)